Skip to content

Author

Eyyup Ayas

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Impact of HER2-low status on survival outcomes in patients with metastatic breast cancer treated with cdk4/6 inhibitors: A single-center experience

Aim: Cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy are recommended as the first-line treatment for hormone receptor-positive, HER2-negative metastatic breast cancer without visceral crisis. However, CDK4/6 inhibitor efficacy has been reported to differ between HER2-low and HER2-zero tumor...

Esra Aydın, Ç. Öztürk, Oğuzhan Okçu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.